

**ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.**

Publicly Traded Company – CVM No. 2612-3

CNPJ/MF No. 12.104.241/0004-02

**Material Fact**

Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3) (the “**Company**”), in compliance with the provisions of Law No. 6,404/76 and CVM Resolution No. 44/21, hereby informs its shareholders and the market in general the following:

The Board of Directors approved, on this date, a proposal for a financing transaction for the Company and OncoProd Distribuidora de Produtos Hospitalares e Oncológicos Ltda. (“**OncoProd**”), presented by MAK Capital Fund LP (“**MAK Capital**”) and Lumina Capital Management LLC (“**Lumina**” and “**Proposal**”, respectively).

The Proposal contemplates a financing transaction for the Company and OncoProd, to be funded by Lumina, in an amount between R\$100 million and R\$150 million (depending on the amount of available collaterals), with the objective of enabling the acquisition of pharmaceutical products by the Company from OncoProd and, thus, preserving the revenue generation of both companies and the continuity of their essential supply chain. The transaction will include the creation of a fiduciary guarantee over receivables arising from agreements entered into by the Company’s accredited network with health plan operators, hospitals, and/or insurers, and its implementation will be subject to the execution of definitive documents and the satisfaction of customary conditions precedent.

The implementation of the transaction will also be subject to specific conditions precedent, including (i) the formalization of the applicable instruments between the Company and OncoProd, (ii) the determination of the amount of receivables to be assigned in trust in an amount compatible with the transaction, and (iii) obtaining the necessary consents from health plan operators, hospitals, and insurers for the pledging and directing of such receivables.

In compliance with the conditions presented by MAK Capital and Lumina to confirm the Proposal, as per written correspondence sent to the Company’s management on April 15, 2026, the Board of Directors also: (i) received the resignation of Mr. Bruno Lemos Ferrari from the positions of member and Vice-Chairman of the Company’s Board of Directors, with immediate effect; and (ii) in order to fill the two vacant positions resulting from the resignations of Messrs. Marcelo Gasparino and Bruno Lemos Ferrari, appointed Mr. Mateus Affonso Bandeira, nominated by MAK Capital, and Mr. Carlos Gil Ferreira, the Company’s Chief Executive Officer, as members of the Company’s Board of Directors, with a term of office until the Company’s Ordinary and Extraordinary General Shareholders’ Meeting called for April 30, 2026 (the “**AEGM**”).

Mr. Mateus Bandeira holds a degree in Computer Science from the Catholic University of Pelotas. He holds a postgraduate degree in Finance from FGV and in Systems Management from UFRGS, with an MBA from The Wharton School, University of Pennsylvania, an OPM (Owners/President Management) Program from Harvard Business School, and a Program for the Development of Technical and Executive Positions in Public Administration from the *Instituto para Reconstrução*

*Industrial.* Mr. Mateus Bandeira currently serves as Chairman of the Board of Directors of CVC Corp. He is a member of the Boards of Directors of Vibra Energia, Sabesp, and Intelbras. He was a member of the Board of Directors of Marcopolo and Oi, where he also served as Coordinator of the People Committee and member of the Operations Committee, and served as CEO of Oi. In 2024, he was Chairman of the Board of Directors of Serede and Tahto, both members of the Oi Group.

Accordingly, until the AEGM is held, the Company's Board of Directors will be composed of Carlos Gil Ferreira, Eduardo Soares do Couto Filho, Marcel Cecchi Vieira, Marcelo Curti, Marcos Grodetzky, Mateus Affonso Bandeira, and Raul Rosenthal Ladeira de Matos.

The members of the Board of Directors thanked Mr. Bruno Lemos Ferrari, as founder, shareholder, and former executive of the Company, for his contribution and dedication over 16 years.

The Company's management remains available to its shareholders and the market in general for any clarifications.

São Paulo, April 16, 2026

**Oncoclínicas do Brasil Serviços Médicos S.A.**

**Marcel Cecchi Vieira**

Executive Vice-President, Chief Financial Officer, and Chief Investor Relations Officer